Use of the protein C reactive in the prevention of the aterosclerose: Between jupiter and marte;Uso Da proteína C reativa na prevenção da aterosclerose: Entre jupiter e marte

Revista da Associacao Medica Brasileira

Volumn 55, Issue 5, 2009, Pages 502-504

  Miname, Marcio H ^a   Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450172422     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302009000500003     Document Type: Editorial

References (17)

1. Cholesterol Treatment Trialists'(CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
2. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
3. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, et al. IV Brazilian Guideline for Dyslipidemia and Atherosclerosis preven-tion: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq Bras Cardiol. 2007;88(Suppl 1):2-19.
4. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial in-farction in the ypung adult in the first place: how do the national cholesterol education panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475-9.
5. Santos RD, Nasir K. Insights into atherosclerosis from invasive and non-invasive imaging studies: should we treat subclinical atherosclerosis? Athe-rosclerosis. 2008;205(2):349-56.
6. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in athe-rothrombosis. Clin Chem. 2009;55(2):229-38.
7. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-38.
8. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-9.
9. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
10. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engs-tröm G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49-57.
11. Pepe MS, Janes H, Longton G, Leisering W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic or screening marker. Am J Epidemiol. 2004;159:882-90.
12. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80mg and pravastatin 40mg in achieving the dual goals of low-density lipoprotein cholesterol <70mg/dL and C-reactive protein <2mg/L. J Am Coll Cardiol. 2005;45:1644-8.
13. DA Morrow, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-8.
14. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
15. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
16. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-82.
17. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S. Implications of the JUPITER (Justification for the use of statins in primary prevention: an intervetion trial evaluating rosuvastatin) Study. J Am Coll Cardiol. 2009;53:931-5.